Trial Profile
A prospective randomized parallel group study of combination treatments of Olmesartan/Azelnidipine against Olmesartan/Indapamide on Osteoprotegerin in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2015
Price :
$35
*
At a glance
- Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary) ; Indapamide
- Indications Essential hypertension
- Focus Pharmacodynamics
- 16 Oct 2015 New trial record